GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tiziana Life Sciences Ltd (NAS:TLSA) » Definitions » EPS (Diluted)

Tiziana Life Sciences (Tiziana Life Sciences) EPS (Diluted) : $-0.18 (TTM As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Tiziana Life Sciences EPS (Diluted)?

Tiziana Life Sciences's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was $-0.08. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.18.

Tiziana Life Sciences's EPS (Basic) for the six months ended in Jun. 2023 was $-0.08. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.18.

Tiziana Life Sciences's EPS without NRI for the six months ended in Jun. 2023 was $-0.08. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.18.

During the past 3 years, the average EPS without NRIGrowth Rate was -14.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was -41.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Tiziana Life Sciences's highest 3-Year average EPS without NRI Growth Rate was 47.60% per year. The lowest was -273.30% per year. And the median was -33.00% per year.


Tiziana Life Sciences EPS (Diluted) Historical Data

The historical data trend for Tiziana Life Sciences's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tiziana Life Sciences EPS (Diluted) Chart

Tiziana Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 -0.10 -0.27 -0.24 -0.15

Tiziana Life Sciences Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.20 -0.04 -0.05 -0.10 -0.08

Competitive Comparison of Tiziana Life Sciences's EPS (Diluted)

For the Biotechnology subindustry, Tiziana Life Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tiziana Life Sciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tiziana Life Sciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Tiziana Life Sciences's PE Ratio falls into.



Tiziana Life Sciences EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Tiziana Life Sciences's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-15.397-0)/101.526
=-0.15

Tiziana Life Sciences's Diluted EPS for the quarter that ended in Jun. 2023 is calculated as

Diluted EPS (Q: Jun. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-8.617-0)/102.273
=-0.08

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tiziana Life Sciences  (NAS:TLSA) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Tiziana Life Sciences EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Tiziana Life Sciences's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Tiziana Life Sciences (Tiziana Life Sciences) Business Description

Traded in Other Exchanges
Address
2 Church Street, Clarendon House, Hamilton, BMU, HM 11
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.

Tiziana Life Sciences (Tiziana Life Sciences) Headlines

From GuruFocus